Trial Profile
A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 21 Jul 2006 New trial record.